New drug could be a breakthrough in treatment for killer TB, trial suggests

Why in news

The WHO and TB Alliance reported promising trial results for a new antibiotic, sorfequiline, which could shorten treatment times for drug-sensitive tuberculosis.

Background

The TB Alliance and WHO are monitoring the trial of sorfequiline, a new antibiotic. The drug aims to shorten treatment duration and improve cure rates for patients testing positive for drug-sensitive tuberculosis.

Facts for Prelims

• S&TSorfequiline: A new antibiotic being trialed to treat drug-sensitive tuberculosis.
• BodyTB Alliance: An organization involved in research and advocacy for tuberculosis treatment.
• BodyWHO: The World Health Organization reported the progress of the sorfequiline trials.

For Mains

Q. Discuss the challenges in managing global tuberculosis and the importance of diversifying antibiotic research to combat drug-resistant strains.

Dimensions to cover in your answer

• R&D bottleneck: Risk of reduced investment in broader healthcare innovations due to over-reliance on single-drug breakthroughs
• Diagnostic gap: Need for faster diagnosis to facilitate the rapid deployment of shortened treatment regimens

Keywords: Public Health · Antibiotic Resistance · Drug-Sensitive Tuberculosis · Clinical Trials · Global Health Governance

More Science & Technology notes

• Cop30 live: Scientists warn countries must act decisively to protect people and life or risk ‘suffering for billions’ – as it happened · 20 November 2025
• The rainforest the world forgot: the Congo basin is the second largest on Earth, so why is it being neglected? · 20 November 2025

All Science & Technology current affairs →

Something wrong, or something missing?

Spotted a mistake in a note, or want a topic, format or PDF that would help your preparation? Write to us. We read every mail and fix errors fast.

Report a mistake →Ask for something →[email protected]